9-13 May 2012 • Barcelona, Spain - Estro-events.org
9-13 May 2012 • Barcelona, Spain - Estro-events.org
9-13 May 2012 • Barcelona, Spain - Estro-events.org
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
9-<strong>13</strong> <strong>May</strong> <strong>2012</strong> <strong>•</strong> <strong>Barcelona</strong>, <strong>Spain</strong><br />
ESTRO<br />
I FInal announcement I<br />
9-<strong>13</strong> <strong>May</strong> <strong>2012</strong> <strong>•</strong> <strong>Barcelona</strong>, <strong>Spain</strong><br />
31
Table of<br />
con conTen enTs<br />
CME ACCREDITATION<br />
The conference <strong>org</strong>anizers have applied for CMe accreditation with the<br />
accreditation Council of Oncology in europe (aCOe) & european accreditation<br />
Council for Continuing Medical education (eaCCMe).<br />
DEADLINES<br />
abstract submission deadline: 16 January <strong>2012</strong><br />
early registration: 12 January <strong>2012</strong><br />
Late registration: 10 April <strong>2012</strong><br />
Desk registration: as of 11 April <strong>2012</strong><br />
ESTRO<br />
31<br />
<strong>2012</strong><br />
> InTRODuCTIOn 4<br />
> SCIenTIFIC COMMITTeeS 5<br />
> PRe-MeeTIng COuRSeS 6<br />
> WHaT’S neW aT eSTRO 31? 11<br />
> COnTOuRIng WORKSHOPS 12<br />
> SCIenTIFIC PROgRaMMe <strong>13</strong><br />
> aWaRDS 22<br />
> CaLL FOR abSTRaCTS 23<br />
> geneRaL InFORMaTIOn 26<br />
> RegISTRaTIOn 28<br />
> aCCOMMODaTIOn 30<br />
> MeMbeRSHIP 32<br />
Page 2 /// FInal announcement /// eSTRO 31 eSTRO 31 /// FInal announcement /// Page 3
Vincenzo Valentini<br />
Introduct<br />
ntroductIon on<br />
a LeTTeR OF WeLCOMe FROM THe COnFeRenCe CHaIRPeRSOnS<br />
It is our pleasure to invite you to attend eSTRO 31 in barcelona from 9 to <strong>13</strong> <strong>May</strong> <strong>2012</strong>.<br />
eSTRO is an interdisciplinary society where radiation oncologists, medical physicists, biologists,<br />
radiation technologists and nurses work for the benefit of cancer patients, looking at the collaboration<br />
with all the <strong>org</strong>anisations in force in the oncology field. In eSTRO 31 the multidisciplinarity<br />
and interdisciplinary components of our practice will be reviewed, emphasising on<br />
the new opportunities that they represent for all of us. national Societies and allied Oncology<br />
Organisations will convene to join efforts in promoting standards and outcome survey.<br />
at eSTRO 31 meeting the most up-to-date evidence in clinical, physics, radiobiology and oncology<br />
science and technology will be presented, and a broad portfolio of educational opportunities will be<br />
provided. Life in the eSTRO house will also be enlightened by special interdisciplinary sessions in a<br />
dedicated room which will jointly address relevant topics for radiation oncologists, physicists, radiobiologists<br />
and RTTs in the same forum, allowing each discipline to enrich their knowledge base.<br />
Symposia and debates are foreseen on new evidence - for the more common tumours and for the<br />
Núria Jornet<br />
challenging unusual clinical presentations - as well as in biology, imaging, physics and technology.<br />
This includes the integration of molecular and genetic prediction of tumour and normal tissue response, the<br />
combination of radiation therapy with new and more efficient molecular targeted drugs, a more extensive use<br />
of particle therapies to better spare normal tissues, a complete integration of 4D image guided treatments,<br />
the development of adaptive radiation therapy to the most active part of the tumours as defined by functional<br />
imaging and the curative use of stereotactic radiotherapy. all these advances challenge machine and patient<br />
specific Qa and dosimetry as well as the training and practice of radiation technologists.<br />
eSTRO 31 will start with a series of pre-meeting workshops and courses which will be followed by an<br />
opening ceremony in the evening.<br />
after the great success of the contouring workshops at eSTRO 29 in barcelona and London, we will continue<br />
with this initiative. Keep an eye on upcoming eSTRO communications to learn more about the tumour sites<br />
that will be covered.<br />
as in previous conferences, eSTRO 31 will continue to offer an additional Young Scientists Track. This track is<br />
fully <strong>org</strong>anised by our young members and it enables them to share common interests.<br />
The number of submitted abstracts to eSTRO meetings increases year after year. Therefore, eSTRO 31 will include<br />
a large poster exhibition and a poster reception on the Thursday evening. The challenge we now face is to<br />
increase the visibility and display of these posters and to facilitate networking between professionals working on<br />
the same or similar topics. Poster viewing will be improved by a better distribution in time and space of posters;<br />
by a special electronic poster viewing system that will be available during the whole conference; and also, by<br />
special poster discussion sessions which will ensure maximum visibility for the most promising posters.<br />
all of the leading exhibitors will contribute to eSTRO 31, europe’s largest industrial exhibition in radiation oncology,<br />
offering the opportunity to view the latest products and services in cancer treatment and cancer care.<br />
Sincerely,<br />
Vincenzo Valentini & Núria Jornet<br />
Chairpersons of the Scientific Programme Committee<br />
Scientific<br />
committee<br />
ommitteeS<br />
eSTRO 31<br />
SCIenTIFIC PROgRaMMe COMMITTee<br />
chaIrs: V. Valentini (IT), n. Jornet (eS)<br />
members: M. baumann (De), J. bourhis (FR ), C. Clark (gb),<br />
D. ge<strong>org</strong> (aT ), C. Haie-Meder (FR ), D. Hollywood (Ie),<br />
T. Knöös (Se ), P. Lambin (nL), M. Mast (nL), L. Muren (DK),<br />
J. Overgaard (DK), D. Pasini (IT), R. Pötter (De), S. Rivera<br />
(FR), H. P. Rodemann (De), F. Stewart (nL), D. Verellen (be),<br />
b. Wouters (Ca)<br />
SCIenTIFIC aDVISORY COMMITTee<br />
OF YOung eSTRO MeMbeRS<br />
chaIrs: C. Clark (gb), S. Rivera (FR)<br />
members: P. blanchard (FR), b. eberle (CH), a. Filippi (IT),<br />
e. gershkevitsh (ee), J. Jaal (ee), M. niyazi (De), D. Jurado<br />
(eS), M. Krause (De), L. Livi (IT), P. Munck af Rosenschöld<br />
(DK), F. Moura (PT), P. Petrič (SL), K. Tanderup (DK)<br />
SCIenTIFIC aDVISORY COMMITTee<br />
CLInICaL RaDIOTHeRaPY<br />
chaIr: D. Hollywood (Ie)<br />
members: C. belka (De), S. bodis (CH), R. Dziadziuszko<br />
(PO), J. giralt (eS), C. grau (DK), K. Harrington (gb),<br />
K. Haustermans (be), b. Jereczek-Fossa (IT), a. Kiltie<br />
(gb), V. Khoo (gb), e. Lartigau (FR), P. Maingon (FR),<br />
a.H. Ree (nO), M. Verheij (nL), D. Zips (De)<br />
SCIenTIFIC aDVISORY COMMITTee<br />
bRaCHYTHeRaPY<br />
chaIr: C. Haie-Meder (FR)<br />
members: a. bossi (FR), P. Hoskin (gb), g. Kovács (De),<br />
J.C. Lindegaard (DK), a. Polo (eS), C. Polgár (Hu), F.a.<br />
Siebert (De), J. Skowronek (PO), e. Van Limbergen (be),<br />
J. Venselaar (nL)<br />
ESTRO<br />
31<br />
<strong>2012</strong><br />
SCIenTIFIC aDVISORY COMMITTee<br />
RaDIaTIOn PHYSICS<br />
chaIr: T. Knöös (Se)<br />
members: M. do Carmo Lopes (PT), C. Fiorino (IT), R. garcia<br />
(FR), D. ge<strong>org</strong> (aT), b. Heijmen (nL), C. Hurkmans (nL),<br />
b. Mc Clean (Ie), R. Moeckli (CH), H. nyström (Se), D.R.<br />
Olsen (nO), C. brink (DK), C. garibaldi (IT), C. Kirisits<br />
(aT), J. Malicki (PO), H. Palmans (gb), D. Thwaites (auS),<br />
a. Torresin (IT), u. Van der Heide (nL), T. Wiezorek (De)<br />
SCIenTIFIC aDVISORY COMMITTee<br />
RaDIObIOLOgY<br />
chaIr: b. Wouters (Ca)<br />
members: J. alsner (DK), a. begg (nL), W. Dörr (De), J. Kaanders<br />
(nL), R. Tarnawski (PO), T. brunner (gb), n. Cordes (De),<br />
T. Helleday (gb), P.C. Lara (eS), M. Martin (FR), M. Pruschy<br />
(CH), H. P. Rodemann (De), M.C. Vozenin (FR)<br />
SCIenTIFIC aDVISORY COMMITTee<br />
RaDIaTIOn TeCHnOLOgY<br />
chaIrs: D. Pasini (IT), M. Mast (nL)<br />
members: a. boejen (DK), M. Coffey (Ie), V. Karadza (HR),<br />
M. Kamphuis (nL), g. McColl (nL), a. Osztavics (aT),<br />
b. Speleers (be), a. Vaandering (be)<br />
LOCaL ORganISIng COMMITTee<br />
chaIrs: a. Ramos aguerri (eS), C. Munoz Montplet (eS)<br />
Page 4 /// FInal announcement /// eSTRO 31 eSTRO 31 /// FInal announcement /// Page 5
Pre re-M -Meeting eeting CCourses<br />
ourses<br />
CLInICaL PRe-MeeTIng COuRSe <strong>•</strong> WeDneSDaY, 9 MaY <strong>2012</strong><br />
InnOVaTIOn In IMagIng ReLeVanT FOR THe RaDIaTIOn OnCOLOgISTS anD THe RaDIOLOgISTS<br />
Jointly <strong>org</strong>anised with ESOR<br />
course dIrectors:<br />
P. Lambin (nL) and L. Marti-bonmarti (eS)<br />
course aIms:<br />
This course, jointly <strong>org</strong>anized by eSTRO and eSOR (european School of Radiology), aims at promoting an integrated approach<br />
between specialists involved in multidisciplinary tumour boards to tailor the best treatment for each individual<br />
patient by exploiting the use of imaging.<br />
new advanced imaging technology not only provides morphological information on tumour extension, but also information<br />
on tumour function and biology. It not only allows a good evaluation of tumour response during and after treatment,<br />
but also an early detection of tumour recurrence. Radiation oncologists increasingly use hybrid equipment in which<br />
diagnostic imaging technology is incorporated within the radiation treatment machines to allow continuous adaptation<br />
of radiation treatment according to the daily response of the tumour, the surrounding <strong>org</strong>ans and their movement.<br />
Thus there is a growing interest to enhance the collaboration between imaging specialists to optimise and to adapt the<br />
different uses of imaging to the comprehensive clinical management of the oncological patient.<br />
by the combination of lectures and case discussions, this course aims to offer a programme focusing on the use of imaging<br />
in a truly multidisciplinary environment to support understanding between different specialists’ needs, practising<br />
common language and delineating research perspectives.<br />
Who should attend?<br />
The target group consists of radiation oncologists and senior residents and junior radiologists who are interested in<br />
learning and improving their knowledge on an optimal approach to multidisciplinary treatment management exploiting<br />
the use of imaging.<br />
content:<br />
<strong>•</strong> Innovation in hardware: PeT- MR, dual energy CT,<br />
<strong>•</strong> Quantification of imaging: standardisation in PeT, diffusion MR, quantification of response, how to get more out of<br />
imaging,<br />
<strong>•</strong> What do we need to know in a multidisciplinary tumour board? Head and neck cancer, lung cancer, prostate cancer,<br />
rectum cancer.<br />
RaDIObIOLOgY PRe-MeeTIng COuRSe <strong>•</strong> WeDneSDaY, 9 MaY <strong>2012</strong><br />
ESTRO<br />
31<br />
<strong>2012</strong><br />
COMbInIng RaDIaTIOn WITH TaRgeTeD THeRaPIeS: COnCePTS, OPPORTunITIeS anD PITFaLLS<br />
course dIrectors:<br />
C. Vens (nL) and a. Chalmers (gb)<br />
course aIms:<br />
Research into the mechanisms underlying resistance of tumours to radiation therapy has identified a number of key pathways<br />
that could be targeted in order to improve tumour control. and advances in drug development have provided us<br />
with new drugs to manipulate these pathways. but only a few of these targeted agents have been successfully combined<br />
with radiation therapy in the clinic, and the results have been mixed. The aim of this course is to provide an overview of<br />
the key concepts and pathways involved, and to discuss progress made and problems encountered in bringing radiation/<br />
targeted therapy combinations to the clinic.<br />
Who should attend the course?<br />
The course is targeted at radiation oncologists who may be aware of the existence of targeted therapies, and may even<br />
have prescribed them, but would like to learn more. In particular we will try to explain why and how these agents can<br />
be combined with radiation therapy. Research or scientific experience is not required, but the course will also be of<br />
interest to scientists undertaking radiation related research.<br />
content:<br />
The course will provide an overview of targeted therapy concepts in four areas that are relevant to radiation responses<br />
of tumours:<br />
<strong>•</strong> Dna damage responses (including Dna repair and cell cycle checkpoints),<br />
<strong>•</strong> Signal transduction pathways (including egFR, PI3K and related pathways),<br />
<strong>•</strong> Tumour microenvironment (including hypoxia, integrins and cancer stem cells),<br />
<strong>•</strong> angiogenesis.<br />
There will then be a session on how to determine which patients are likely to benefit from which combinations. This<br />
will include aspects of biomarker development including imaging, pathology, clinical features and molecular subtyping.<br />
The final session will focus on clinical application of these concepts. Here we will consider what we have learned from<br />
those clinical trials that have been conducted – both positive and negative – and how we can select the best drugs and<br />
design the best clinical studies. The course will finish with a vision of the future in which combinations of radiation and<br />
targeted therapies are considered to be ‘standard of care’.<br />
a panel of invited international speakers will provide high quality talks that are specifically tailored to our target audience.<br />
In between talks there will be lots of opportunities (and much encouragement) for spirited discussion involving<br />
faculty and delegates.<br />
Page 6 /// FInal announcement /// eSTRO 31 eSTRO 31 /// FInal announcement /// Page 7
PHYSICS PRe-MeeTIng COuRSe <strong>•</strong> WeDneSDaY, 9 MaY <strong>2012</strong><br />
course dIrector:<br />
H. nyström (Se)<br />
Pre re-M -Meeting eeting CCourses<br />
ourses<br />
WHaT a PHYSICIST SHOuLD COnSIDeR beFORe gOIng InTO a PROTOn THeRaPY PROJeCT<br />
course aIms:<br />
In many countries in europe as well as in the rest of the world, proton therapy facilities are either in the process of<br />
being created or are already well-established. In fact, the increase in the number of new facilities has been more or<br />
less exponential for many years, leading to an increased demand for medical physicists capable of carrying out proton<br />
therapy projects.<br />
There are many obvious advantages when using proton therapy compared to conventional photon based radiotherapy,<br />
since a significantly larger fraction of the absorbed dose is actually delivered to the target volumes and an overall superior<br />
dose distribution is achieved.<br />
However, substantial differences exist in terms of technology, treatment planning, dosimetry, Qa etc. What is a reasonable<br />
staffing level? What is a reasonable “business plan”? How should acceptance testing be performed? What are<br />
the demands for clinical commissioning? What are the demands for treatment planning? What are the demands for Qa?<br />
This course aims at answering a few of the above-mentioned questions and at giving an overview of the particular aspects<br />
of radiotherapy that are specific to proton therapy. In particular those involved in the start up phase of a proton<br />
therapy project or those that are considering entering into such a project would benefit from participation.<br />
Who should attend?<br />
The participant in the course is expected to be a medical physicist experienced in conventional radiotherapy but curious<br />
about proton therapy.<br />
content:<br />
<strong>•</strong> Introduction to the physics and basic dosimetry of protons,<br />
<strong>•</strong> acceptance testing and clinical commissioning of scanned and scattered proton beams,<br />
<strong>•</strong> Treatment planning for protons, including margin concepts,<br />
<strong>•</strong> CT scanning and the handling of image artefacts,<br />
<strong>•</strong> Obtaining an efficient patient flow in a multi gantry PT facility,<br />
<strong>•</strong> Qa and verification planning.<br />
ESTRO<br />
31<br />
<strong>2012</strong><br />
PHYSICS PRe-MeeTIng COuRSe <strong>•</strong> WeDneSDaY, 9 MaY <strong>2012</strong><br />
JoIntly <strong>org</strong>anIsed by gec-estro brachyphysIcs group and estro physIcs commIttee<br />
ReCenT aDVanCeS In bRaCHYTHeRaPY PHYSICS<br />
course dIrectors:<br />
J. LM Venselaar (nL) and D. baltas (De)<br />
course aIms:<br />
<strong>•</strong> To demonstrate the most recent developments in brachytherapy physics: a discussion on recent and future societal<br />
reports and recommendations,<br />
<strong>•</strong> To discuss the developments in source calibration, quality assurance, and new equipment,<br />
<strong>•</strong> To discuss the steps towards modern 3D conformal image based brachytherapy,<br />
<strong>•</strong> To discuss new and forthcoming advanced treatment planning: model based dose calculation algorithms and inverse<br />
planning and optimisation methodologies in intensity modulated brachytherapy,<br />
<strong>•</strong> To discuss the similarities and differences between modern 3D conformal eRT and bRT and its consequences for the<br />
concepts of margins.<br />
Who should attend?<br />
The course is aimed primarily at medical physicists and medical physicists in training, and at radiation technologists<br />
willing to update themselves on the latest developments in brachytherapy physics. a basic knowledge of brachytherapy<br />
physics is required.<br />
content:<br />
<strong>•</strong> Status of present day brachytherapy physics: weak and strong points, challenges and possibilities, and recent technological<br />
developments,<br />
<strong>•</strong> Calibration of sources, RaKR/Sk, and/or dose-to-water concept (iMeRa project); dosimetry chain from PSDL to enduser,<br />
<strong>•</strong> new approaches in brachytherapy dose calculation: model based dose calculation algorithms (MC, grid based boltzmann<br />
solvers, primary/scatter separation),<br />
<strong>•</strong> Inverse planning and optimisation methodologies in intensity modulated brachytherapy,<br />
<strong>•</strong> Image guided brachytherapy: use of CT and MRI, uS (and PeT) in bT, choice of settings, sequences, fusion, functional<br />
imaging,<br />
<strong>•</strong> Specific Qa requirements for modern imaging procedures in RT and bT,<br />
<strong>•</strong> uncertainties associated with the physical aspects: calibration and dose calculation,<br />
<strong>•</strong> uncertainties associated with the clinical steps: accuracy in imaging, reconstruction, delivery, implications of inter/<br />
intrafraction movement,<br />
<strong>•</strong> Similarities and differences in modern 3D conformal eRT and bRT and its consequences for margin concepts,<br />
<strong>•</strong> In-vivo dosimetry: techniques and possible applications.<br />
Page 8 /// FInal announcement /// eSTRO 31 eSTRO 31 /// FInal announcement /// Page 9
Pre re-M -Meeting eeting CCourses<br />
ourses Scientific<br />
cientific PProgramme<br />
rogramme<br />
RTT PRe-MeeTIng COuRSe <strong>•</strong> WeDneSDaY, 9 MaY <strong>2012</strong><br />
THe DeLIneaTIOn OF nORMaL STRuCTuReS: PRaCTICe anD CHaLLengeS<br />
course dIrectors:<br />
D. Pasini (IT) and S. Rivera (FR)<br />
course aIms:<br />
Intensity Modulated Radiotherapy Techniques (Static or rotational IMRT-techniques) rather than uniform intensity techniques<br />
give the ability to conform dose distributions to a variety of complex tumour sites/volumes while sparing nearby<br />
critical normal tissue structures (OaR) as possible.<br />
The QuanTeC reports have summarised the evidence from a wide range of studies relating to the dose tolerance of the<br />
main OaRs. Several of the reports highlight the issue of the normal tissue delineation considering both anatomical and<br />
functional aspects.<br />
In order to achieve a greater level of accuracy in the definition of OaRs, there is an urgent need to improve the knowledge<br />
of the anatomical limits of some selected structures. It is therefore important to become familiar with contouring<br />
procedures on the different imaging modalities implemented in the treatment planning systems, without neglecting the<br />
<strong>org</strong>an dose-volume tolerance.<br />
This course will specifically focus on the anatomical definition of normal structures within the head and neck, thorax<br />
and pelvic regions.<br />
an introductory lecture will illustrate the meaning of OaR delineation within the frame of the QuanTeC report.<br />
The following section will be <strong>org</strong>anised in:<br />
1) a first theoretical part for each site, where an expert will give an overview of the delineation of the selected <strong>org</strong>an/s<br />
at risk in accordance with the QuanTeC recommendations,<br />
2) It will be followed by a practical session in which the participants will have the opportunity to apply their knowledge<br />
in practice with the support of the faculty. They will be asked to contour <strong>org</strong>ans on FaLCOn, an e-learning software<br />
tool based on the eDuCaSe platform of eSTRO which has already been used successfully during previous workshops<br />
on target volume delineation.<br />
In preparation for the course and to ensure maximum benefit, the participants will be asked to use the FaLCOn platform<br />
at home to delineate selected <strong>org</strong>ans at risk. The same exercise will be repeated during the course and, after the experts’<br />
lectures, the comparison between the exercises will be discussed by the teachers using FaLCOn tools.<br />
as an outcome of the course we would like the participants to review their clinical practice in the context of the new<br />
recommendations of normal structure delineation and QuanTeC guidelines.<br />
Who should attend?<br />
This course is designed for radiation technologists involved in planning and radiation oncologists in training.<br />
content:<br />
<strong>•</strong> anatomical definition of selected normal structures,<br />
<strong>•</strong> Review of dose-volume tolerance for the selected <strong>org</strong>ans based on the new evidences,<br />
<strong>•</strong> Improving the practice on contouring.<br />
WHaT’S neW aT eSTRO 31?<br />
ESTRO<br />
31<br />
<strong>2012</strong><br />
1. The scientific programme of eSTRO 31 will be enriched by special sessions in an ‘Interdisciplinary Track’ where relevant<br />
topics for radiation oncologists, physicists, radiobiologists and RTTs will be addressed jointly. not sure which<br />
sessions you could attend? To make it more convenient for you, for each session of this track, the discipline of relevance<br />
is indicated.<br />
2. Have a closer look at the ‘Look Inside’ (LI) sessions. The format of these sessions allows for approximately 66% of the<br />
time for presentation of theory followed by approximately 33% of the time for illustration via practical examples.<br />
3. Debates (D) have been designed in the Oxford example with point and counterpoint discussions followed by conclusions<br />
in support and against of the stance taken by the debaters.<br />
4. We continue in the tradition of Joint Sessions (JS) with other societies such as aSTRO, eau, eCCO, eFOMP, eSMO,<br />
eSSO, eORTC, eanM and PROS.<br />
5. need some guidance in deciding which sessions would be most beneficial for you to attend? Here are the topics<br />
that will be addressed on the main conference days.<br />
thursday, 10 may <strong>2012</strong><br />
The small volume challenge; Cutting edge technology; Data management and networks; Targeting perspective in<br />
Radiobiology; adaptive RT: changing the practice<br />
FrIday, 11 may <strong>2012</strong><br />
The children, young and elderly patients deal; Theragnostic and Imaging in RT; Quality assurance of new techniques<br />
and technologies; Microenvironment<br />
saturday, 12 may <strong>2012</strong><br />
Current practice and moving controversies; Dosimetry challenges; Theragnostic and Imaging in RT; normal tissue;<br />
Radiobiological principles for RTT practice<br />
sunday, <strong>13</strong> may <strong>2012</strong><br />
Current practice and moving controversies; Predictive biomarkers in RT; Dose calculation and optimization; Looking<br />
forward; Stem cells; RTT responsibilities and involvement in research<br />
Page 10 /// FInal announcement /// eSTRO 31 eSTRO 31 /// FInal announcement /// Page 11
workshops<br />
orkshops<br />
COnTOuRIng WORKSHOPS<br />
Inconsistencies in contouring target and critical structures can seriously undermine the precision of conformal radiation<br />
therapy planning and are generally considered to be the biggest and most unpredictable source of errors in radiation<br />
oncology.<br />
eSTRO started with the <strong>org</strong>anisation of contouring sessions in barcelona at eSTRO 29.<br />
This first experience was very positive and the barcelona sessions were quickly fully booked.<br />
The Scientific Committee of the London meeting and the eSTRO education and Training committee therefore decided to<br />
repeat these very useful workshops in 2011 and in the meantime they have become an indispensable and very attractive<br />
part of the annual meeting.<br />
at eSTRO 31 in barcelona, we will be pleased to offer the 4 contouring workshops to a limited number of participants<br />
(60/workshop) on the following sites:<br />
prostate<br />
breast<br />
gynaecology<br />
CnS<br />
The main aims will be to strengthen hands-on contouring skills and discuss the intercomparison of the different delineated<br />
volumes with experts in the field and colleagues from all over the world. Participants will be allowed to bring their<br />
own laptop or use an eSTRO laptop to participate online.<br />
For more details on the experts chairing these workshops and the practical <strong>org</strong>anisation please check the eSTRO website:<br />
www.estro-<strong>events</strong>.<strong>org</strong>/Pages/eSTRO31.aspx<br />
We recommend not to wait too long to register or you might discover<br />
that the workshop you want to attend is already fully booked!<br />
Scientific<br />
Programme<br />
rogramme<br />
PRE-MEETINg COuRSES <strong>•</strong> WEDNESDAy, 9 MAy <strong>2012</strong><br />
ESTRO<br />
31<br />
<strong>2012</strong><br />
CliniCal Radiobiology PhysiCs PhysiCs RTT<br />
Innovation in imaging<br />
relevant to the<br />
Radiation Oncologist<br />
and the Radiologist<br />
Page 12 /// FInal announcement /// eSTRO 31 eSTRO 31 /// FInal announcement /// Page <strong>13</strong><br />
18:00 –<br />
19:15<br />
19:30<br />
Course DIrector:<br />
P. Lambin (NL) and<br />
L. Marti-Bonmarti (ES)<br />
OPenIng CeReMOnY<br />
WeLCOMe ReCePTIOn<br />
Combining radiation What a physicist<br />
with targeted therapies: should consider before<br />
concepts, opportunities going into a proton<br />
and pitfalls<br />
therapy project<br />
course DIrectors:<br />
A. Chalmers (GB)<br />
and C. Vens (NL)<br />
course DIrector:<br />
H. Nyström (SE)<br />
See pages 6-10 for complete information on pre-meeting courses<br />
Recent advances in<br />
brachytherapy physics<br />
course DIrectors:<br />
D. Baltas (DE)<br />
and J. Venselaar (NL)<br />
The delineation of<br />
normal structures:<br />
practice and challenges<br />
course DIrectors:<br />
D. Pasini (IT)<br />
and S. Rivera (IT)
BARCELONA <strong>•</strong> ThuRSDAy, 10 MAy <strong>2012</strong><br />
Scientific<br />
cientific PProgramme<br />
rogramme<br />
clInIcal clInIcal InterdIscIplInary physIcs physIcs radIobIology RTT<br />
Adaptive<br />
radiotherapy:<br />
changing the<br />
practice<br />
Targeting<br />
Data<br />
management<br />
and networks<br />
Cutting edge<br />
technology<br />
The small volume challenge<br />
topIcs<br />
oF the day<br />
JOInT WITH<br />
InTeRDISCIPLInaRY<br />
TL<br />
The DNA damage response<br />
following irradiation and<br />
its significance<br />
TL<br />
Biostatistics<br />
for medical<br />
physicists<br />
TL<br />
Flattening filter free<br />
photon beams<br />
TL<br />
Adaptive radiotherapy state<br />
of the art<br />
TL<br />
When is hypofractionation<br />
mandatory:<br />
the radiobiologist’s and<br />
clinician’s point of view?<br />
TL<br />
Extra cranial stereotactic:<br />
from technical<br />
availabilities to clinical<br />
opportunities<br />
08:00 – 08:40<br />
JOInT WITH<br />
InTeRDISCIPLInaRY<br />
S<br />
Synthetic lethal approaches<br />
in radiotherapy<br />
- exploiting mutations<br />
<strong>•</strong> exploiting hypoxia<br />
dependent Dna repair<br />
defects<br />
<strong>•</strong> The use of functional<br />
screens to identify novel<br />
targets of radiosensitisation<br />
<strong>•</strong> Synthetic lethal<br />
approaches for RaS using<br />
biologics<br />
S<br />
hot research issues in<br />
ion beam therapy<br />
<strong>•</strong> Ion species beyond<br />
protons and carbon<br />
ions<br />
<strong>•</strong> Single particle tomography<br />
for verifying<br />
ion beam delivery<br />
<strong>•</strong> Treatment planning:<br />
integrating robustness<br />
in optimisation<br />
Sa<br />
Adaptive radiotherapy:<br />
opportunities and pitfalls<br />
CL, Ph, BRT, RB, RTT<br />
<strong>•</strong> Decision rules for re-planning<br />
<strong>•</strong> Can deformable registration<br />
approaches be reliable?<br />
<strong>•</strong> Strategies for dose accumulation<br />
in adaptive radiation<br />
therapy<br />
<strong>•</strong> biological adaptation strategies<br />
JS<br />
ESTRO - EAu<br />
The challenge of treating<br />
early intermediate risk prostate<br />
cancer<br />
<strong>•</strong> Is dose escalation appropriate?<br />
<strong>•</strong> Innovative surgery:<br />
opportunities and constraints<br />
- Robotic<br />
<strong>•</strong> Innovative surgery: opportunities<br />
and constraints<br />
- Laparoscopic<br />
<strong>•</strong> The role of androgen blockade<br />
combined with radiotherapy<br />
S<br />
Clinical achievements in<br />
extra cranial stereotactic:<br />
facts or promises<br />
<strong>•</strong> Stages I-II nSCLC<br />
<strong>•</strong> Liver<br />
<strong>•</strong> Spinal / paraspinal<br />
08:45 – 10:00<br />
10:00 – 10:30 COFFee bReaK<br />
PP PP PP PP<br />
10:30 – 11:30 PP PP Sb<br />
Adaptive radiotherapy: how<br />
to handle the tumour modification<br />
along the treatment<br />
CL, Ph, BRT, RB, RTT<br />
<strong>•</strong> Head and neck<br />
<strong>•</strong> Lung<br />
<strong>•</strong> gynaecology<br />
PRESIDENTIAL SyMPOSIuM: The reverse angle perspective<br />
<strong>•</strong> Rapid Learning Health care & Randomised trial: are the two approaches antagonistic or complementary? - P. Lambin (NL)<br />
<strong>•</strong> What is the scientific community expecting from eSTRO to build a multidisciplinary platform in europe? - C. van de Velde (NL)<br />
11:45 – 12:30<br />
SESSIONS: TL= Teaching Lecture / S = Symposium /JS = Joint Symposium / D = Debate / PP = Proffered Papers / LI = Look Inside / EU = Session on EU Projects<br />
DISCIPLINES: CL= Clinical / PH= Physics / BRT= Brachytherapy / RB= Radiobiology / RTT= Radiation Technology<br />
Page 14 /// FInal announcement /// eSTRO 31 eSTRO 31 /// FInal announcement /// Page 15<br />
clInIcal clInIcal InterdIscIplInary physIcs physIcs radIobIology RTT<br />
aWaRD LeCTuRe (Van DeR SCHueRen)<br />
12:30 – <strong>13</strong>.00<br />
<strong>13</strong>:00 – 14:30 LunCH anD InDuSTRY SYMPOSIa<br />
S<br />
Adaptive radiotherapy:<br />
changing the practice<br />
<strong>•</strong> aRT: Problems &<br />
possible solutions for<br />
RTTs<br />
<strong>•</strong> aRT in Head and<br />
neck: how it affects<br />
the practice<br />
<strong>•</strong> aRT by gating<br />
<strong>•</strong> aRT in brachytherapy<br />
S<br />
Radiotherapy and the<br />
immune system, immunological<br />
aspects of<br />
treatment response to<br />
ionizing radiation<br />
<strong>•</strong> Role of CD8+ and<br />
dendritic cells in the<br />
treatment response<br />
to ionizing radiation<br />
<strong>•</strong> TgF-β signalling orchestrates<br />
late renal<br />
toxicity by regulating<br />
the immune response<br />
after irradiation<br />
<strong>•</strong> effects of modulated<br />
immune responses on<br />
epithelial radiation<br />
effects during fractionated<br />
irradiation<br />
JS<br />
ESTRO - EFOMP<br />
Sharing information and<br />
communication in radiation<br />
oncology<br />
<strong>•</strong> Workflow in radiotherapy.<br />
network architecture and<br />
transmission standards from<br />
the images to treatment and<br />
dosimetric verification<br />
<strong>•</strong> Improving standards for<br />
interoperability in radiation<br />
oncology:<br />
DICOM and IHe-RO<br />
<strong>•</strong> networking and connectivity<br />
in radiotherapy: opportunities<br />
and risks<br />
<strong>•</strong> Internationally advanced computer<br />
network for research<br />
and decision supporting<br />
software<br />
LI<br />
Cutting edge technology;<br />
can we deliver<br />
the dose distribution<br />
we plan?<br />
<strong>•</strong> external radiation<br />
therapy with photons<br />
<strong>•</strong> Ion beam therapy<br />
<strong>•</strong> brachytherapy<br />
S<br />
Brachytherapy boost<br />
or SIB: treatment of<br />
choice for prostate<br />
cancer?<br />
CL, Ph, BRT<br />
<strong>•</strong> Imaging in target<br />
definition<br />
<strong>•</strong> Comparison between<br />
brachytherapy and<br />
ebT with x-rays<br />
and protons. Dose<br />
distributions and<br />
peripheral doses<br />
<strong>•</strong> emerging data for<br />
high risk patients<br />
S<br />
hypofractionation and<br />
volume effect in breast<br />
cancer<br />
<strong>•</strong> update of hypofractionation<br />
in WbRT and<br />
implications for PbRT<br />
<strong>•</strong> How important is the<br />
volume effect for late<br />
adverse effects after<br />
aPbI?<br />
<strong>•</strong> update of IORT trials<br />
<strong>•</strong> update of brachytherapy<br />
trials<br />
JS<br />
ESTRO - ECCO<br />
Ethics in professional<br />
life<br />
14:30 – 15:45<br />
15:45 – 16:15 COFFee bReaK<br />
PP PP D<br />
This house believes<br />
that daily verification<br />
and image analysis is<br />
solely the responsibility<br />
of the radiation<br />
oncologist<br />
D<br />
This house believes<br />
that process-based<br />
quality management<br />
replaces today’s quality<br />
controls<br />
16:15 - 17:15 PP PP D<br />
Debate: This house<br />
believes that brachytherapy<br />
is the best<br />
technique for partial<br />
breast irradiation<br />
CL, BRT<br />
HIgHLIgHTS OF THe PROFFeReD PaPeRS<br />
17:30 – 18:30<br />
POSTeR ReCePTIOn - POSTeR aWaRDS<br />
18:30 – 19:30<br />
SESSIONS: TL= Teaching Lecture / S = Symposium /JS = Joint Symposium / D = Debate / PP = Proffered Papers / LI = Look Inside / EU = Session on EU Projects<br />
DISCIPLINES: CL= Clinical / PH= Physics / BRT= Brachytherapy / RB= Radiobiology / RTT= Radiation Technology
BARCELONA <strong>•</strong> FRIDAy, 11 MAy <strong>2012</strong><br />
Scientific<br />
cientific PProgramme<br />
rogramme<br />
clInIcal clInIcal InterdIscIplInary physIcs physIcs radIobIology RTT young<br />
Microenvironment Elderly patients<br />
in radiotherapy<br />
departments<br />
Quality assurance<br />
of new techniques<br />
and technologies<br />
Theragnostic and imaging<br />
in radiotherapy<br />
The children, young<br />
and elderly patients deal<br />
topIcs<br />
oF the day<br />
TL<br />
how to design your<br />
study<br />
TL<br />
Increased number<br />
of elderly cancer<br />
patients: general<br />
overview<br />
TL<br />
Clinical relevance<br />
of tumour microenvironment<br />
and<br />
metabolism<br />
TL<br />
Streamlining IMRT<br />
QA<br />
TL<br />
Physical and geometricaluncertainties<br />
in functional<br />
imaging and how to<br />
deal with them<br />
TL<br />
Decision support<br />
systems: requirements,implementation<br />
and evaluation<br />
TL<br />
Current practice<br />
and moving points:<br />
paediatrics<br />
08:00 – 08:40<br />
JOInT WITH RTTs<br />
S<br />
Oncology safety:<br />
learning from<br />
experience<br />
<strong>•</strong> Physics perspective<br />
on incidents<br />
<strong>•</strong> Clinician perspective<br />
on incidents<br />
<strong>•</strong> Incidents in related<br />
areas: surgery<br />
<strong>•</strong> Incidents in related<br />
areas: medical<br />
oncology<br />
<strong>•</strong> Discussion<br />
S<br />
Radiotherapy in<br />
elderly: where are<br />
we aiming for in the<br />
future<br />
<strong>•</strong> elderly with<br />
cancer: is it necessary<br />
to change<br />
the radiotherapy<br />
protocol?<br />
<strong>•</strong> Informing and<br />
communicating<br />
with elderly radiotherapy<br />
patients<br />
<strong>•</strong> guidelines to<br />
treat patients<br />
with orthopaedic<br />
prosthesis<br />
S<br />
Tumour microenvironment<br />
– novel<br />
biology and novel<br />
targets<br />
<strong>•</strong> Microenvironmental<br />
response to<br />
phosphoinositide-3<br />
kinase inhibition:<br />
effects on cancer<br />
therapy<br />
<strong>•</strong> novel targets of<br />
hypoxia tolerance<br />
<strong>•</strong> Targeting vasculogenesis<br />
to improve<br />
radiation response<br />
S<br />
Dose assessment<br />
during treatment;<br />
towards greater<br />
control of the dose<br />
delivered to the<br />
patient<br />
<strong>•</strong> Dose reconstruction<br />
using dynamic<br />
log files and CbCT<br />
<strong>•</strong> Dose reconstruction<br />
using ePID<br />
and CbCT<br />
<strong>•</strong> Dose reconstruction<br />
in tomotherapy<br />
<strong>•</strong> Implantable MOS-<br />
FeT dosimeters<br />
Sa<br />
Emerging imaging<br />
technologies –applications<br />
in radiation<br />
oncology<br />
CL, Ph, RB<br />
<strong>•</strong> Radiomics:<br />
advanced image<br />
processing<br />
approach<br />
<strong>•</strong> new tracers<br />
<strong>•</strong> Dual energy CT<br />
<strong>•</strong> MRI and PeT scanner<br />
JS<br />
ESTRO – ESMO – ESSO<br />
young adult<br />
patients: the maximum<br />
derivable or<br />
the minimum effective<br />
treatment<br />
<strong>•</strong> Combined treatments<br />
in Hodgkin<br />
disease: the radiotherapy<br />
optimal<br />
dose<br />
<strong>•</strong> breast cancer in<br />
young women:<br />
adjuvant therapy<br />
and fertility considerations<br />
<strong>•</strong> Combined treatment<br />
rectal: young<br />
adult patients<br />
JS<br />
ESTRO - PROS<br />
Complex multimodel<br />
approaches:<br />
Paediatrics<br />
<strong>•</strong> new perspectives<br />
with protons /<br />
particles<br />
<strong>•</strong> new knowledge<br />
on late effects:<br />
second primary<br />
cancers, cardiac<br />
and cerebrovascular<br />
diseases<br />
<strong>•</strong> Technical advances<br />
in radiotherapy for<br />
medulloblastoma:<br />
yesterday, today,<br />
tomorrow<br />
<strong>•</strong> update on neuroblastoma<br />
08:45 – 10:00<br />
10:00 – 10:30 COFFee bReaK<br />
10:30 – 11:30 SeLeCTeD RanDOMIZeD TRIaLS PP PP PP<br />
hIghLIghTS OF RANDOMISED TRIALS<br />
11:45 – 12:15<br />
aWaRD LeCTuRe (RegauD)<br />
12:15 – <strong>13</strong>:00<br />
<strong>13</strong>:00 – 14:30 LunCH anD InDuSTRY SYMPOSIa Lunch symposium:<br />
Education and working<br />
around Europe<br />
SESSIONS: TL= Teaching Lecture / S = Symposium /JS = Joint Symposium / D = Debate / PP = Proffered Papers / LI = Look Inside / EU = Session on EU Projects<br />
DISCIPLINES: CL= Clinical / PH= Physics / BRT= Brachytherapy / RB= Radiobiology / RTT= Radiation Technology<br />
Page 16 /// FInal announcement /// eSTRO 31 eSTRO 31 /// FInal announcement /// Page 17<br />
clInIcal InterdIscIplInary physIcs physIcs radIobIology RTT young<br />
S<br />
ESTRO<br />
contract<br />
with the<br />
young<br />
JOInT<br />
WITH<br />
CLInICIanS<br />
LI<br />
Does fractionated<br />
radiation therapy make<br />
tumours more aggressive?<br />
<strong>•</strong> Radiation induced<br />
changes in cell-cell and<br />
cell-matrix<br />
<strong>•</strong> Vascular and metabolic<br />
responses to tumour<br />
irradiation<br />
<strong>•</strong> TgFbeta: dual roles<br />
in the response of<br />
tumours and normal<br />
tissues to radiation<br />
LI<br />
Tracking: techniques, methods,<br />
dosimetric and QA aspects<br />
<strong>•</strong> Motivation for real-time adaptive<br />
therapy (what problems<br />
are solved, how important is<br />
this potentially, what level of<br />
evidence is there)<br />
<strong>•</strong> approaches for motion detection<br />
and trajectory prediction<br />
<strong>•</strong> Clinical commissioning and clinical<br />
experience of real-time<br />
adaptation<br />
S<br />
Imaging for treatment<br />
assessment<br />
<strong>•</strong> Cone beam CT based<br />
measurement of dose<br />
response in normal lung<br />
<strong>•</strong> Diffusion-weighted MRI<br />
for prediction and early<br />
treatment assessment of<br />
chemoradiation in head<br />
and neck cancer<br />
<strong>•</strong> assessment of head and<br />
neck toxicity using CT<br />
Sb<br />
Emerging imaging<br />
technologies – how<br />
functional imaging<br />
will impact our<br />
practice<br />
CL, Ph, RB<br />
<strong>•</strong> Prostate<br />
<strong>•</strong> brain<br />
<strong>•</strong> Lymphoma<br />
<strong>•</strong> Lung<br />
S<br />
Elderly patients’ treatment:<br />
standards vs. feasibility<br />
<strong>•</strong> The elderly tsunami<br />
<strong>•</strong> Importance of age and comorbidity<br />
for the outcome<br />
radiotherapy in head and<br />
neck cancer. a population<br />
based study<br />
<strong>•</strong> The limits in delivery of chemotherapy<br />
in the elderly:<br />
the breast model<br />
<strong>•</strong> Comprehensive assessment<br />
in elderly patients with<br />
cancer<br />
14:30 – 15:45<br />
15:45 – 16:15 COFFee bReaK Moving<br />
poster<br />
16:15 – 17:15 S<br />
PP S<br />
PP D<br />
PP PP<br />
session<br />
Elderly patients treatment:<br />
Can imaging be<br />
Why should we do pre-treat-<br />
standards vs. feasibility<br />
quantitative?<br />
ment QA for IMRT when we<br />
<strong>•</strong> Primary radiotherapy:<br />
CL, RB<br />
didn’t do it for conformal<br />
head and neck<br />
<strong>•</strong> Multi-centric<br />
therapy?<br />
<strong>•</strong> neoadjuvant radiotherapy:<br />
calibration of PeT<br />
Lower gI<br />
<strong>•</strong> Validation of<br />
<strong>•</strong> adjuvant and definitive<br />
imaging<br />
radiotherapy in elderly<br />
<strong>•</strong> What can automa-<br />
patients with lung cancer<br />
tic PeT tumour volume<br />
delineation<br />
bring to treatment<br />
planning?<br />
17:30 – 18:00 aWaRD LeCTuRe (IRIDIuM) COMPanY aWaRD LeCTuReS (VaRIan, J. FOWLeR)<br />
eSTRO SCHOOL SYMPOSIuM anD ReCePTIOn<br />
18:00 – 19:00<br />
SESSIONS: TL= Teaching Lecture / S = Symposium /JS = Joint Symposium / D = Debate / PP = Proffered Papers / LI = Look Inside / EU = Session on EU Projects<br />
DISCIPLINES: CL= Clinical / PH= Physics / BRT= Brachytherapy / RB= Radiobiology / RTT= Radiation Technology
BARCELONA <strong>•</strong> SATuRDAy, 12 MAy <strong>2012</strong><br />
Scientific<br />
cientific PProgramme<br />
rogramme<br />
clInIcal clInIcal InterdIscIplInary physIcs physIcs radIobIology RTT<br />
Normal tissue Radiobiological<br />
principles<br />
Current practice and moving controversies Dosimetry challenges Theragnostic and<br />
imaging in radiotherapy<br />
topIcs<br />
oF the day<br />
TL<br />
Radiobiological<br />
principles: an<br />
overview<br />
TL<br />
Molecular pathology<br />
of normal tissue<br />
effects<br />
TL<br />
Overview of dose volume<br />
parameters used<br />
in clinical practice and<br />
recommendations<br />
(EBRT and brachytherapy)<br />
TL<br />
Small photon field<br />
dosimetry challenges in<br />
relative-absolute and<br />
reference dosimetry<br />
TL<br />
Current practice: new<br />
targeted agents and radiotherapy<br />
in clinical trials<br />
TL<br />
Standards and<br />
uncertainties in<br />
radiotherapy of the<br />
upper abdomen<br />
TL<br />
Current practice and moving<br />
points: lung<br />
08:00 – 08:40<br />
S<br />
Radiobiology<br />
principles:<br />
dose fractionation<br />
<strong>•</strong> Radiobiological<br />
principles:<br />
what the RTTs<br />
need to know<br />
<strong>•</strong> Hyperfractionation:<br />
general<br />
overview<br />
<strong>•</strong> accelerated<br />
treatment in<br />
breast cancer<br />
<strong>•</strong> Hypofractionation:<br />
general<br />
overview<br />
S<br />
Novel clinical<br />
strategies to reduce<br />
normal tissue injuiry<br />
<strong>•</strong> Stem cell therapy<br />
to ameliorate<br />
radiation damage<br />
in salivary glands<br />
<strong>•</strong> attenuation and<br />
reversion of<br />
radiation induced<br />
fibrosis by an anti<br />
CTgF monoclonal<br />
antibody<br />
<strong>•</strong> Development of<br />
novel mitigators of<br />
radiation damage<br />
S<br />
ultrasound in brachytherapy<br />
<strong>•</strong> uS physics: basics and<br />
new developments<br />
<strong>•</strong> uS for treatment<br />
planning in prostate<br />
<strong>•</strong> uS for treatment<br />
planning in gynaecology<br />
S<br />
Dosimetry challenges<br />
when moving away from<br />
reference conditions<br />
<strong>•</strong> TRS-398 12 years later:<br />
review of new data and<br />
application to novel<br />
treatment units<br />
<strong>•</strong> Dosimetric commissioning<br />
of rotational<br />
treatment units<br />
<strong>•</strong> Dosimetry in strong<br />
magnetic fields: issues<br />
and opportunities<br />
<strong>•</strong> Dosimetric concepts<br />
based on particle track<br />
structure<br />
S<br />
Novel drugs and RT<br />
CL, RB<br />
<strong>•</strong> Synthetic lethal approaches<br />
to using drugs<br />
with radiation<br />
<strong>•</strong> The need and challenge<br />
of introducing biomarkers<br />
in phase 1-2 trials of<br />
radiotherapy and novel<br />
targeted agents<br />
<strong>•</strong> Design and conduct of<br />
early-phase radiotherapy<br />
trials with targeted<br />
therapeutics<br />
<strong>•</strong> The head and neck model<br />
S<br />
Complex multimodel<br />
approaches:<br />
upper gI<br />
<strong>•</strong> Multidisciplinary<br />
management of<br />
operable gastric<br />
cancer<br />
<strong>•</strong> Complex multimodal<br />
approaches<br />
for oesophagus and<br />
OgJ tumours<br />
<strong>•</strong> Complex multimodel<br />
approaches<br />
for pancreatic<br />
tumours<br />
S<br />
Critical assessment of the<br />
potential of research strategies<br />
to improve outcome of<br />
advanced NSCLC<br />
<strong>•</strong> Image-guidance<br />
<strong>•</strong> Dose escalation and fractionation<br />
<strong>•</strong> Combined modalities including<br />
chemoradiation and<br />
molecular targeting<br />
<strong>•</strong> Particle therapy<br />
08:45 – 10:00<br />
10:00 – 10:30 COFFEE BREAK<br />
PP PP PP PP<br />
PP J S<br />
ESTRO – EORTC<br />
CL, Ph, RB, RTT<br />
<strong>•</strong> Qa and credentialing:<br />
global status and future<br />
challenges<br />
<strong>•</strong> a radiation oncologist<br />
view on trial Qa<br />
<strong>•</strong> Qa makes a trial stronger<br />
S<br />
Complex multi-model approaches:<br />
lung<br />
<strong>•</strong> Chemoradiation In nSCLC:<br />
divided past, common<br />
future?<br />
<strong>•</strong> Postop radiotherapy/ current<br />
guidelines and moving<br />
points<br />
<strong>•</strong> Target drugs and radiotherapy<br />
(both nSCLC and SCLC)<br />
10:30 – 11:30<br />
SESSIONS: TL= Teaching Lecture / S = Symposium /JS = Joint Symposium / D = Debate / PP = Proffered Papers / LI = Look Inside / EU = Session on EU Projects<br />
DISCIPLINES: CL= Clinical / PH= Physics / BRT= Brachytherapy / RB= Radiobiology / RTT= Radiation Technology<br />
Page 18 /// FInal announcement /// eSTRO 31 eSTRO 31 /// FInal announcement /// Page 19<br />
clInIcal clInIcal InterdIscIplInary physIcs physIcs radIobIology RTT<br />
HOnORaRY MeMbeRS LeCTuReS<br />
11:45 – 12:30<br />
aWaRD LeCTuRe (bReuR)<br />
12:30 – <strong>13</strong>:00<br />
<strong>13</strong>:00 – 14:30 LunCH anD InDuSTRY SYMPOSIa<br />
S<br />
Radiobiology principles:<br />
dose modifiers<br />
<strong>•</strong> Is there a need for<br />
interval between drug<br />
and radiotherapy<br />
delivery?<br />
<strong>•</strong> Side effects with dose<br />
modifier relevant for<br />
RTT: general overview<br />
<strong>•</strong> Radioprotectors: general<br />
overview<br />
S<br />
heterogeneity in treatment<br />
response: the way to personalised<br />
treatment<br />
<strong>•</strong> egFR signalling as a basis<br />
for personalised medicine<br />
<strong>•</strong> The importance of RaS<br />
mutations for targeted<br />
therapy in colon cancer<br />
<strong>•</strong> Hypoxia signatures predict<br />
benefit from radiosensitisers<br />
PP S<br />
PET and MR imaging possibilities<br />
and pitfalls when used for<br />
radiotherapy<br />
<strong>•</strong> Impact of image reconstruction<br />
and quantitative analysis<br />
on PeT for radiotherapy<br />
planning<br />
<strong>•</strong> The use of MRI in radiotherapy<br />
planning: potential<br />
pitfalls and solutions<br />
<strong>•</strong> Dynamic and diffusion weighted<br />
MRI: how to use it for<br />
radiotherapy<br />
14:30– 15:45 PP PP S<br />
Extreme hypofractionation<br />
CL, Ph, RB, RTT<br />
<strong>•</strong> biological consideration<br />
of high dose per<br />
fraction<br />
<strong>•</strong> High dose rate: a new<br />
opportunity?<br />
<strong>•</strong> Managing delivery of<br />
high dose fraction<br />
<strong>•</strong> assessment of effect<br />
and outcome<br />
15:45 – 16:15 COFFee bReaK<br />
PP<br />
D<br />
This house believes that<br />
SNPs will be useful predictors<br />
of normal tissue<br />
response in the future<br />
D<br />
This house<br />
believes<br />
that 1%<br />
improved<br />
dosimetric<br />
accuracy<br />
is more<br />
valuable<br />
than 1 mm<br />
less PTV<br />
margin<br />
JS<br />
ESTRO – ASTRO<br />
New technologies<br />
in radiation oncology<br />
are always better:<br />
fact of fiction?<br />
<strong>•</strong> Protons<br />
<strong>•</strong> IMRT: the potential<br />
use and benefit of<br />
dose escalation<br />
<strong>•</strong> IgRT: the challenge<br />
& potential for intraprostatic<br />
boosts<br />
Eu<br />
ARTFORCE<br />
ANDANTE<br />
JS<br />
ESTRO - EANM<br />
The future of radio-isotope<br />
therapies (bone mets, thyroid,<br />
neuroendocrine, lymphoma)<br />
<strong>•</strong> Radium-223 in the treatment<br />
of advanced prostate cancer<br />
<strong>•</strong> Translational studies on pretargeted<br />
radio-immunotherapy<br />
of colorectal cancer<br />
<strong>•</strong> Radiolabelled somatostatin<br />
analogues in neuroendocrine<br />
tumours<br />
16:15 – 17:15<br />
geneRaL aSSeMbLY<br />
17:30 – 19:30<br />
SOCIaL eVenIng<br />
20:00<br />
SESSIONS: TL= Teaching Lecture / S = Symposium /JS = Joint Symposium / D = Debate / PP = Proffered Papers / LI = Look Inside / EU = Session on EU Projects<br />
DISCIPLINES: CL= Clinical / PH= Physics / BRT= Brachytherapy / RB= Radiobiology / RTT= Radiation Technology
BARCELONA <strong>•</strong> SuNDAy, <strong>13</strong> MAy <strong>2012</strong><br />
Scientific<br />
cientific PProgramme<br />
rogramme<br />
clInIcal clInIcal InterdIscIplInary physIcs physIcs radIobIology RTT<br />
Looking forward Stem cells RTT responsibilities<br />
and involvement in<br />
research<br />
Dose calculation and<br />
optimisation<br />
Predictive biomarkers<br />
in radiotherapy<br />
Current practice and<br />
moving controversies<br />
topIcs<br />
oF the day<br />
TL<br />
RTT responsibilities<br />
and involvement in<br />
research<br />
TL<br />
What is a stem cell and<br />
why should I care<br />
TL<br />
Models for secondary<br />
cancer induction at<br />
radiotherapy dose.<br />
An update<br />
TL<br />
Biological optimisation<br />
in the clinic<br />
TL<br />
New clinical fractionation<br />
models in head<br />
and neck radiation<br />
therapy<br />
TL<br />
Current practice and<br />
moving points: sarcoma<br />
TL<br />
Current practice and<br />
moving points:<br />
primary brain<br />
08:30 – 09:10<br />
S<br />
RTT responsibilities<br />
and involvement in<br />
research<br />
<strong>•</strong> The role of the imaging<br />
specialist RTT<br />
<strong>•</strong> From mould to planning<br />
<strong>•</strong> How to plan and<br />
implement a clinical<br />
research RTT project<br />
in the department<br />
D<br />
how important are<br />
tumour and normal<br />
tissue stem cells in<br />
radiotherapy<br />
S<br />
Nanoparticles in radiotherapy<br />
<strong>•</strong> green nanotechnology<br />
in molecular<br />
imaging and therapy<br />
<strong>•</strong> Physical perspective<br />
on radiation<br />
response modulation<br />
of tumours with gold<br />
nanoparticles<br />
<strong>•</strong> gold nanoparticles as<br />
radiosensitisers<br />
<strong>•</strong> Monte Carlo simulation<br />
on dose enhancement<br />
S<br />
Advances in dose calculation<br />
and optimisation<br />
algorithms. Improving<br />
planning efficacy and<br />
plan quality<br />
<strong>•</strong> MCO for IMRT planning<br />
<strong>•</strong> MCO in radiation<br />
oncology: from priorisation<br />
to interaction<br />
<strong>•</strong> Fast and accurate<br />
solution of the<br />
boltzmann radiation<br />
transport equation for<br />
radiotherapy. Theoretical<br />
aspects<br />
<strong>•</strong> Fast and accurate<br />
solution of the<br />
boltzmann radiation<br />
transport equation<br />
for radiotherapy.<br />
Implementation and<br />
validation<br />
S<br />
how deep does hPV<br />
change h&N treatment<br />
strategy?<br />
CL, RB<br />
<strong>•</strong> epidemiology and<br />
clinical features<br />
<strong>•</strong> biology and targeting<br />
of HPV<br />
<strong>•</strong> HPV positive vs. HPV<br />
negative oropharyngeal<br />
carcinoma:<br />
de-escalating vs.<br />
intensified treatment?<br />
S<br />
Prediction of complete<br />
response can enhance<br />
<strong>org</strong>an preservation in<br />
rectal cancer<br />
<strong>•</strong> pCR: a subgroup<br />
of patients with<br />
better survival or<br />
a unsafe surrogate<br />
endpoint<br />
<strong>•</strong> Diffusion MR prediction:<br />
standard<br />
or research<br />
<strong>•</strong> PeT-CT prediction<br />
of response of rectal<br />
cancer to neoadjuvant<br />
therapy:<br />
standard or research<br />
<strong>•</strong> Modelling response<br />
prediction on clinical<br />
and imaging<br />
evidences<br />
S<br />
Current practice and<br />
controversies: brain<br />
tumours<br />
<strong>•</strong> Combination of<br />
targeted drugs with<br />
radiotherapy in<br />
glioblastoma : from<br />
mechanisms to<br />
therapy<br />
<strong>•</strong> Low grade gliomas<br />
/ treatment<br />
sequence (current<br />
practice and future<br />
trends)<br />
<strong>•</strong> brain metastases<br />
09:15 – 10:30<br />
10:30 – 11:00 COFFee bReaK<br />
SESSIONS: TL= Teaching Lecture / S = Symposium /JS = Joint Symposium / D = Debate / PP = Proffered Papers / LI = Look Inside / EU = Session on EU Projects<br />
DISCIPLINES: CL= Clinical / PH= Physics / BRT= Brachytherapy / RB= Radiobiology / RTT= Radiation Technology<br />
Page 20 /// FInal announcement /// eSTRO 31 eSTRO 31 /// FInal announcement /// Page 21<br />
clInIcal clInIcal InterdIscIplInary physIcs physIcs radIobIology RTT<br />
S<br />
Comparison studies:<br />
ongoing research<br />
<strong>•</strong> gynaecological radiotherapy:<br />
a study to<br />
compare 2D gynaecological<br />
radiotherapy<br />
with IMRT: an ongoing<br />
trial in Ireland<br />
<strong>•</strong> Ongoing research: Fu<br />
data of a moderate<br />
hypo-fractionation<br />
scheme<br />
<strong>•</strong> Delineation of rectal<br />
carcinoma: comparison<br />
between prone<br />
and supine position<br />
S<br />
MC platforms, getting<br />
MC easy for routine use<br />
in MP<br />
<strong>•</strong> SMCP - an efficient<br />
Monte Carlo treatment<br />
planning system<br />
<strong>•</strong> egSnrc, beaMnrc<br />
Eu<br />
MEDRAPET<br />
uLICE<br />
S<br />
Predictive biomarkers<br />
in radiotherapy<br />
CL, Ph, RB<br />
<strong>•</strong> Preclinical predictive<br />
essays and<br />
platforms<br />
<strong>•</strong> Do our mother’s<br />
genes influence tolerance<br />
to radiation?<br />
<strong>•</strong> use in clinical trials<br />
S<br />
head and neck design:<br />
Radiotherapy techniques<br />
requirements<br />
<strong>•</strong> IMRT for which<br />
patients and for what<br />
benefit?<br />
<strong>•</strong> IMRT + IgRT and/or<br />
adaptive<br />
<strong>•</strong> IMRT for nPC<br />
D<br />
This house believes<br />
that there is still a<br />
role for radiotherapy<br />
in intermediate risk<br />
endometrial cancer<br />
11:00 – 12:00<br />
D2<br />
The house believes that biological optimisation supersedes physical optimisation<br />
12:00 – 12:45<br />
SESSIONS: TL= Teaching Lecture / S = Symposium /JS = Joint Symposium / D = Debate / PP = Proffered Papers / LI = Look Inside / EU = Session on EU Projects<br />
DISCIPLINES: CL= Clinical / PH= Physics / BRT= Brachytherapy / RB= Radiobiology / RTT= Radiation Technology
AwArds rds Call all for abstra bstraCts ts<br />
*** ESTRO – VARIAN AWARD ***<br />
prIze deFInItIon<br />
a prize of 7500 € will be given to a radiotherapy professional for research in the field of radiobiology, radiation physics,<br />
clinical radiotherapy or radiation technology.<br />
crIterIa For elIgIbIlIty<br />
Candidates should be:<br />
1. eSTRO members, having completed the submitted work in the previous year.<br />
Submissions should be sent by the candidates or their department heads and may be work done as an individual piece<br />
of research or as a thesis complete in the field of biological, physical and clinical research.<br />
2. Younger than 36. exceptions will be made for female applicants who had to interrupt their research for pregnancy/<br />
maternity reasons; for them the maximum age is fixed at 40.<br />
Candidates should submit:<br />
<strong>•</strong> a curriculum vitae and a list of publications<br />
<strong>•</strong> an abstract of the project for eSTRO 31<br />
<strong>•</strong> an english summary of their work (max 2 pages)<br />
The candidates should commit themselves to write an original paper in english on (part of) the scientific work carried<br />
out. This paper should be based on previously unpublished data and should be written according to the “Instructions to<br />
authors” of the Journal “Radiotherapy and Oncology” in which it will be published, if accepted.<br />
*** ESTRO – JACK FOWLER uNIVERSITy OF WISCONSIN AWARD 2011 ***<br />
a single prize of 1000 € will be given for the best abstract in the field of radiation physics or radiation technology,<br />
submitted for eSTRO 31.<br />
crIterIa For elIgIbIlIty<br />
Candidates should be:<br />
1. eSTRO members.<br />
2. Younger than 36. exceptions will be made for female applicants who had to interrupt their research for pregnancy/<br />
maternity reasons; for them the maximum age is fixed at 40.<br />
Candidates should submit:<br />
<strong>•</strong> a curriculum vitae,<br />
<strong>•</strong> a letter from their department head stating that the work has been done by the applicant,<br />
<strong>•</strong> an abstract on radiation physics or radiation technology for presentation at eSTRO 31.<br />
Applications for awards are to be addressed to:<br />
ESTRO Office <strong>•</strong> Av. E. Mounierlaan, 83 <strong>•</strong> 1200 Brussels <strong>•</strong> Belgium<br />
Tel: +32.2.775 93 40 <strong>•</strong> Fax: +32.2.779 54 94 <strong>•</strong> awards@estro.<strong>org</strong><br />
DEADLINE FOR SuBMISSION: 16 JANuARy <strong>2012</strong><br />
guIDeLIneS FOR SubMISSIOn OF abSTRaCTS<br />
nOTe: OnLY One abSTRaCT aS PReSenTIng auTHOR Can be SubMITTeD<br />
abSTRaCT SubMISSIOn DeaDLIne: 16 JANuARy <strong>2012</strong> (MIDnIgHT CeT)<br />
gENERAL INSTRuCTIONS<br />
abstracts must be submitted online via the eSTRO website at: www.estro.<strong>org</strong>.<br />
For questions regarding the online submission process, please e-mail <strong>events</strong>@estro.<strong>org</strong>.<br />
REguLATIONS<br />
ESTRO<br />
31<br />
<strong>2012</strong><br />
With the submission of an abstract for eSTRO 31, the first (presenting) author:<br />
<strong>•</strong> accepts responsibility for the accuracy of the abstract and ascertains that all authors are aware of the content before<br />
submission<br />
<strong>•</strong> accepts to be the contact person for all correspondence related to the abstract and to inform the co-authors about<br />
its status<br />
<strong>•</strong> accepts to identify any financial interest in products or processes described in the abstract. This includes stock<br />
ownership, membership on any advisory boards, commercially sponsored research or any other substantial relationships.<br />
<strong>•</strong> Certifies that the information to be reported is for exclusive presentation in the session to which the abstract will be<br />
assigned, if accepted, and that the information will not be presented as such at any commercially sponsored satellite<br />
symposia during the conference<br />
abstracts must be submitted and presented at the conference in english. The Scientific Committee reserves the right to<br />
reject an abstract written in poor english.<br />
abstracts will be anonymised before review to ensure fairness and eliminate possible bias. Therefore it is strictly for-<br />
bidden to include the authors’ names or institutions in the body of the abstracts. Submitted abstracts that include such<br />
references will be penalised by the abstract Reviewing Committee.<br />
During eSTRO 31 a poster session for authors aged 40 or less will be <strong>org</strong>anised. Please make sure your date of birth is<br />
correct in the eSTRO database.<br />
Page 22 /// FInal announcement /// eSTRO 31 eSTRO 31 /// FInal announcement /// Page 23
ABSTRACT SuBMISSION<br />
abstract Format:<br />
Call all for abstra bstraCts ts<br />
<strong>•</strong> Topic category: choose the topic category that refers to the main subject of the abstract. The Scientific Committee<br />
reserves the right to re-categorise the abstract.<br />
<strong>•</strong> Presentation preference: authors should indicate the presentation preference (oral, poster or no preference). Please<br />
note that the final decision on the presentation format rests with the Scientific Committee.<br />
<strong>•</strong> Keywords: authors are required to provide 1 to 3 keywords (different from category).<br />
<strong>•</strong> Title: abstract titles should be brief and reflect the content of the abstract. The title (maximum 100 characters) is<br />
important since it focuses attention (it is the “showcase” for the presentation). Do not use capital letters in the title<br />
except for words that are always capitalised and do not use non-standard abbreviations.<br />
<strong>•</strong> body of the abstract: abstracts should be structured in such a way as to include (1) Purpose/Objective; (2) Material/<br />
methods; (3) Results (4) Conclusion.<br />
<strong>•</strong> The use of standard abbreviations is desirable. a special or unusual abbreviation must be placed (in round brackets)<br />
after the first appearance of the word for which it stands.<br />
<strong>•</strong> The online abstract submission procedure will not accept abstracts that exceed 2500 characters (body of the abstract,<br />
excluding spaces).<br />
<strong>•</strong> authors can include one data table in the body of the abstract (this is not included in the number of characters).<br />
<strong>•</strong> authors can include one black and white image in JPg format. The maximum file size of each image should be 500<br />
Kb. The maximum pixel size of the image is 600(w) x 800(h) pixel. Colour illustrations will appear in black and white.<br />
<strong>•</strong> equations can be inserted in the text as images (only JPg format).<br />
<strong>•</strong> The preferred font is Verdana 7.<br />
ABSTRACT SELECTION PROCESS<br />
abstracts submitted for presentation will be reviewed by an international panel of experts in the field of the subject.<br />
abstract review criteria are based on clarity, supporting data, scientific rigour, potential significance, interest in the topic<br />
chosen and innovation or usefulness. Research obviously not yet performed and results not yet obtained will be rejected.<br />
abstracts WIll be selected For one oF the FolloWIng presentatIon Formats:<br />
<strong>•</strong> Oral presentation: the abstract is selected for oral presentation at any of the proffered paper sessions.<br />
<strong>•</strong> Poster discussion session: a limited number of the abstracts will be selected for poster presentation. a chairperson<br />
will discuss selected posters with the authors and audience.<br />
<strong>•</strong> Poster presentation: abstracts that have been selected for presentation in a poster format. The posters are grouped by topic<br />
and are displayed throughout the meeting. Only a limited number of abstracts will be selected for poster presentation.<br />
<strong>•</strong> e-poster: abstracts are available for viewing in electronic format in special stations available at the conference venue.<br />
Withdrawal of an abstract: abstracts submitted for eSTRO 31 can be withdrawn until 10 February <strong>2012</strong>. (To withdraw<br />
your abstract you should send an email to <strong>events</strong>@estro.<strong>org</strong>). after this date, withdrawal of abstracts is no longer possible.<br />
abstracts selected for oral / poster discussion / poster presentation should be presented at the meeting. If the<br />
first (presenting) author cannot attend the conference, he / she should assign a replacement and inform the eSTRO<br />
office of the replacement as soon as possible.<br />
notification of outcome of abstract submission will be sent by email by end February <strong>2012</strong>.<br />
LATE-BREAKINg ABSTRACTS<br />
ESTRO<br />
31<br />
<strong>2012</strong><br />
<strong>•</strong> The work and/or update must be novel, ground-breaking, of high significance, evidence-based and with scientific merit.<br />
<strong>•</strong> The work and/or update must be original and not previously have been published or presented at any other scientific meeting.<br />
<strong>•</strong> The abstract must present timely findings that were not available at the time of the deadline (16 January <strong>2012</strong>). The<br />
late breaking abstract deadline is not intended to be a second deadline for abstract submissions.<br />
<strong>•</strong> a limited number of late-breaking abstracts will be accepted.<br />
<strong>•</strong> Submissions will be accepted for oral presentation only.<br />
<strong>•</strong> The deadline for late-breaking abstracts is 20 March <strong>2012</strong>.<br />
ABSTRACT TOPIC CATEgORIES<br />
ClInIcal track<br />
1. CnS and haematology<br />
2. Head and neck<br />
3. Lung<br />
4. breast<br />
5. gastrointestinal tumours (upper and lower gI)<br />
6. genitourinary (prostate included)<br />
7. gynaecological tumours<br />
8. Sarcoma<br />
9. Paediatrics<br />
10. elderly<br />
11. Palliation/supportive care/patient support<br />
12. Stereotactic RT<br />
<strong>13</strong>. Target and volume definition and imaging<br />
14. Health economics<br />
15. Other tumour sites<br />
PhysIcs track<br />
16. basic dosimetry and phantom and detector developments/characterisation<br />
17. Dose measurements<br />
18. Dose calculation<br />
19. Treatment planning and comparisons<br />
20. Treatment plan optimisation<br />
21. Radiobiological modelling<br />
22. Intrafraction motion management<br />
23. Management of interfraction changes<br />
24. Imaging: focus on clinical applications<br />
25. Imaging: focus on Qa and technical aspects<br />
26. Implementation of technology, techniques, clinical<br />
protocols or trials<br />
27. Radiation protection<br />
28. Professional and educational issues<br />
29. Others<br />
radIobIology track<br />
30. Molecular targeted agents and radiotherapy<br />
31. The Dna damage response<br />
32. genomics and proteomics<br />
33. Tumour microenvironment, hypoxia & angiogenesis<br />
34. normal tissue effects: pathogenesis and treatment<br />
35. Predictive assays/prognostic factors<br />
36. novel radiation modalities - particles, high LeT<br />
37. Time dose fractionation<br />
38. Signal transduction<br />
39. Others<br />
RTT track<br />
40. Patient preparation, patient immobilization<br />
and support aids<br />
41. Treatment planning and dose calculation<br />
42. Volume definition, treatment margins and geometric<br />
uncertainties<br />
43. Patient care<br />
44. education and training<br />
Page 24 /// FInal announcement /// eSTRO 31 eSTRO 31 /// FInal announcement /// Page 25
General eneral IInformat<br />
nformatIon on<br />
uPDATED INFORMATION<br />
Please consult the eSTRO website on a regular basis<br />
for updated information: www.estro.<strong>org</strong>.<br />
CALL FOR ABSTRACTS<br />
abstracts must be submitted online through the eSTRO<br />
website which hosts an electronic abstract submission<br />
form. One abstract as presenting author can be submitted.<br />
Deadline for abstract submission is January 16, <strong>2012</strong>.<br />
ONLINE REgISTRATION<br />
Registration to the conference will be exclusively<br />
through our online registration form via the eSTRO<br />
website.<br />
VENuE<br />
CCIb<br />
Rambla Prim 1-17<br />
08019 barcelona, <strong>Spain</strong><br />
www.ccib.es<br />
ACCOMMODATION & CITy TOuRS<br />
The official accommodation agent for the conference<br />
will be ultramar.<br />
In close consultation with us they have made a selection<br />
of hotels in barcelona. We advise you to make<br />
your reservation well in advance. Hotel accommodation<br />
is made on a first-come, first-served basis.<br />
If you wish to take a guided tour of the city please<br />
contact:<br />
Teresa Ibañez<br />
ultramar event Management<br />
Diputació 238-244 3a planta<br />
08007 barcelona<br />
Tel.: +34 93 482 71 63 <strong>•</strong> Fax: +34 93 482 71 54<br />
estro<strong>2012</strong>@ultramar<strong>events</strong>.com<br />
CuRRENCy<br />
The currency in <strong>Spain</strong> is the euro.<br />
OFFICIAL LANguAgE<br />
The official language of the conference is english. no<br />
simultaneous translation will be provided.<br />
POSTERS<br />
electronic poster stations located in the exhibition<br />
hall and in the poster area will allow you to view the<br />
virtual displays at your leisure and to correspond with<br />
presenters or forward a presentation to a colleague<br />
or home office.<br />
Selected posters will also be displayed in the poster<br />
area during the whole conference.<br />
EXhIBITION<br />
an exhibition featuring equipment and medical publishers<br />
will be held in the exhibition area. The opening of the<br />
exhibition will be on Wednesday <strong>May</strong> 9, <strong>2012</strong> at 19.30.<br />
The exhibition will remain open from Thursday <strong>May</strong> 10<br />
to Saturday <strong>May</strong> 12. entrance is free for all registered<br />
participants and accompanying persons.<br />
Companies and publishers who would like to participate<br />
in the exhibition may obtain more detailed information<br />
from the eSTRO Office.<br />
Contact person:<br />
Valérie Cremades – Industry & exhibition Coordinator<br />
Tel.: +32.2.775.93.41 <strong>•</strong> Fax.: +32.2.779.54.94<br />
e-mail: vcremades@estro.<strong>org</strong><br />
INSuRANCE<br />
The <strong>org</strong>aniser does not accept liability for individual<br />
medical, travel or personal insurance. Participants are<br />
strongly advised to take out their own personal insurance<br />
policies.<br />
In case an unforeseen event would force eSTRO to<br />
cancel the meeting, the Society will reimburse the par-<br />
ticipants the registration fee minus 15% for handling<br />
charges. eSTRO will not be responsible for the refund of<br />
travel and accommodation costs.<br />
LuNChEONS AND REFREShMENTS<br />
The registration fee for the conference includes lunch<br />
and coffee breaks to all participants and exhibitors<br />
wearing their conference badges.<br />
OPENINg CEREMONy & WELCOME RECEPTION<br />
all participants, registered accompanying persons and<br />
company delegates are invited to the official opening<br />
ceremony which will be held in the main auditorium<br />
on Wednesday <strong>May</strong> 9, <strong>2012</strong> at 18:00. The opening ceremony<br />
will be followed by the welcome reception<br />
which will take place in the exhibition area.<br />
SATELLITE SyMPOSIA<br />
Commercial satellite symposia will be held during lunch<br />
breaks. The programmes of the symposia will be<br />
published in the official Programme book and on the eSTRO<br />
website. For additional information, please contact:<br />
Valérie Cremades – Industry & exhibition Coordinator<br />
Tel.: +32.2.775.93.41 <strong>•</strong> Fax.: +32.2.779.54.94<br />
e-mail: vcremades@estro.<strong>org</strong><br />
SOCIAL ACTIVITIES<br />
<strong>•</strong> Wednesday, may 9, <strong>2012</strong><br />
all registered participants & accompanying persons<br />
and all company delegates are invited to the<br />
welcome reception which will take place in the<br />
exhibition area as of 19:30 on Wednesday 9 <strong>May</strong>.<br />
<strong>•</strong> saturday, may 12 , <strong>2012</strong><br />
all participants and registered accompanying persons<br />
are invited to the special evening which will<br />
take place in an exclusive venue in barcelona.<br />
ESTRO<br />
31<br />
<strong>2012</strong><br />
hOW TO REACh BARCELONA<br />
<strong>•</strong> el prat InternatIonal aIrport is six miles (10 kilometres)<br />
south-west of the centre of barcelona and taxis are<br />
available at the airport 24 hours a day. It takes about<br />
twenty minutes into the centre of town and the fare<br />
is about 18 €. There’s a RenFe train every 30 minutes<br />
to Sants Station (central barcelona) from 6:00 am to<br />
10:30 pm. The fare is about 1.80 € and the journey<br />
takes about 16 minutes in air-conditioned trains with<br />
plenty of luggage space.<br />
<strong>•</strong> publIc transport In barcelona<br />
The subway is the easiest and fastest way of moving<br />
around the city.<br />
barcelona has got 2 different systems, the subway<br />
with its 5 lines and the FCg, with 2 lines in barcelona<br />
and 4 more lines going to nearby towns.<br />
The bus is certainly a slower transportation but it allows<br />
you to enjoy the city views while moving around.<br />
black and yellow cabs show a green light when free.<br />
Just wave your hand to call them. The meter (it is<br />
compulsory to use them) will indicate the price to<br />
pay, but an extra fee is charged when taking it at<br />
the airport or when you carry luggage with you, etc.<br />
Prices are shown on a sticker inside the cab.<br />
<strong>•</strong> hoW to reach the congress centre<br />
You can reach the CCIb by metro (Maresme-Forum<br />
station in the yellow line), bus (lines number 7, 36,<br />
41, 43 and 141) and Trambesos (Forum station). all<br />
these stops are located just a few minutes’ walking<br />
distance from the CCIb.<br />
Page 26 /// FInal announcement /// eSTRO 31 eSTRO 31 /// FInal announcement /// Page 27
Regist egistRation ation<br />
ONLINE REgISTRATION<br />
Registering through the eSTRO website is simple and<br />
will only take a few minutes. The eSTRO website can be<br />
consulted at www.estro.<strong>org</strong> (click “<strong>events</strong>”, “eSTRO 31”<br />
and then “register online”). Please follow the instructions<br />
included on the electronic registration form before<br />
submitting your registration and do not send it again by<br />
fax or post. Receipt of registration will be acknowledged<br />
electronically.<br />
PAyMENT INFORMATION<br />
Payments can be made either by credit card through<br />
our secured website or by bank transfer.<br />
For payments made by bank transfer 15 € should be<br />
added to the total amount.<br />
For all questions concerning registration and payments,<br />
please contact: <strong>events</strong>@estro.<strong>org</strong>.<br />
REgISTRATION FEE<br />
Reduced fees apply when the payment is received before<br />
specific deadlines:<br />
EaRly REgisTRaTion RaTE dEadlinE: 12 JanuaRy, <strong>2012</strong><br />
laTE REgisTRaTion RaTE dEadlinE: aPRil 10, <strong>2012</strong><br />
dEsk REgisTRaTion RaTE: as of aPRil 11, <strong>2012</strong><br />
Please note that in order to register for this event<br />
at the member price you must renew your membership<br />
for <strong>2012</strong>.<br />
Registration to eSTRO 31 also gives access to the World<br />
Congress of brachytherapy. See the World Congress of<br />
brachytherapy Final announcement or the eSTRO web-<br />
site for the detailed Scientific Programme.<br />
Registration to eSTRO 31 does not give access to the<br />
Conference pre-meeting courses and the Contouring<br />
workshops.<br />
The registration fee to the conference includes access to<br />
the scientific sessions, including the World Congress of<br />
brachytherapy, the exhibition area, the programme and<br />
abstract books, coffee and lunches, the invitation to the<br />
opening reception and the social evening.<br />
The registration fee for accompanying persons includes<br />
access to the opening ceremony and welcome reception,<br />
the social evening and the exhibition area.<br />
CONFIRMATION OF REgISTRATION<br />
upon receipt of your registration, a confirmation of<br />
your registration will be forwarded to you electronically.<br />
CANCELLATION OF REgISTRATION<br />
In case of cancellation, a refund of the registration fee<br />
minus handling charges of 15% may be obtained up to<br />
3 months before the meeting. between 3 months and 1<br />
month before the meeting, the refund will amount to<br />
50% of the fee. no refund will be possible if the cancellation<br />
is postmarked after april 10, <strong>2012</strong>.<br />
Prices DO NOT INCLUDE VAT.<br />
18% VAT will be added at the end of the registration process.<br />
ESTRO<br />
31<br />
<strong>2012</strong><br />
conFerence early late desk<br />
deadlInes 12/01/<strong>2012</strong> 10/04/<strong>2012</strong> as oF 11/04/<strong>2012</strong><br />
1 day registration RTT member 200 € 200 € 200 €<br />
1 day registration eSTRO member<br />
(exc. RTT)<br />
300 € 300 € 300 €<br />
1 day registration non member 415 € 415 € 415 €<br />
Student * 210 € 245 € 300 €<br />
RTT member 250 € 335 € 440 €<br />
Junior Member 285 € 400 € 545 €<br />
Member 355 € 540 € 685 €<br />
non member 600 € 775 € 955 €<br />
accompanying person ** <strong>13</strong>0 € <strong>13</strong>0 € <strong>13</strong>0 €<br />
pre-meetIng courses<br />
RTT member / Junior member / Student 105 € 155 € 225 €<br />
Member 150 € 190 € 245 €<br />
non member 195 € 235 € 290 €<br />
contourIng Workshops 30 € 55 € 110 €<br />
Prices are without VAT. 18% VAT will be added upon payment.<br />
* To register as a student you should send your updated student card after doing the registration and before paying to jill.barnard@estro.<strong>org</strong>, Institute<br />
letters are not accepted.<br />
** The registration fee for accompanying persons includes access to the opening cermony and welcome reception, the social evening and the exhibition area.<br />
Page 28 /// FInal announcement /// eSTRO 31 eSTRO 31 /// FInal announcement /// Page 29
Accommod<br />
ccommodAtion tion<br />
uLTRaMaR is the official agent for the eSTRO 31 Conference and will be offering special reduced rates for accommodation.<br />
accommodation has been arranged for the period of the conference (from <strong>May</strong> 7 th to <strong>13</strong> th <strong>May</strong> <strong>2012</strong>). For earlier arrivals,<br />
later departures or groups with more than 3 persons please contact us: estro<strong>2012</strong>@ultramar<strong>events</strong>.com<br />
To book your accommodation please go to: www.estro-<strong>events</strong>.<strong>org</strong>/Pages/eSTRO31.aspx<br />
Hotel accommodation is subject to availability. In case of extension of nights, the effective rate at the moment of the<br />
request will be applied.<br />
From april 9 th on, all reservations will be On ReQueST.<br />
Full payment should be transferred no later than april, 9 th <strong>2012</strong>. Please note all reservations will be automatically can-<br />
celled if payment is not received by the mentioned dates.<br />
<strong>•</strong> until april 9th 2011, no cancellation fees will be applied.<br />
<strong>•</strong> From april 10th to april 20th , one night will be charged as cancellation penalty.<br />
<strong>•</strong> no refund will be provided for partial or total cancellations after april 20th onwards, neither for no-shows<br />
<strong>•</strong> In case of no-shows, the hotel will automatically release the reservation and full payment will be non-refundable.<br />
all changes/cancellations must be received in writing by fax or email. Please do not contact the hotel directly. no other<br />
means of cancellation will be considered.<br />
accommodatIon secretarIat:<br />
Raquel González<br />
ultramar Event Management<br />
Diputació 238-244 3a planta<br />
08007 <strong>Barcelona</strong><br />
Tel.: +34 93 482 72 46 <strong>•</strong> Fax: +34 93 482 71 54<br />
estro<strong>2012</strong>@ultramar<strong>events</strong>.com<br />
www.estro<strong>2012</strong>accommodation.com<br />
ESTRO<br />
31<br />
<strong>2012</strong><br />
hOTELS CATEgORy SINgLE DOuBLE<br />
Me barcelona 5* 243 € 265 €<br />
Yacht Hotel 5* 240 € 240 €<br />
Medinaceli 4* 200 € 250 €<br />
aC barcelona 4* 211 € 233 €<br />
Hilton Diagonal Mar 4* 210 € 240 €<br />
barcelona Princess 4* 200 € 222 €<br />
Diagonal Zero 4* 190 € 210 €<br />
Hesperia del Mar 4* 179 € 189 €<br />
Vincci Marítimo 4* 155 € 175 €<br />
Tryp Condal Mar 4* 168 € 179 €<br />
Confortel barcelona 4* 162 € 173 €<br />
novotel barcelona City 4* 160 € 180 €<br />
Silken Diagonal barcelona 4* 160 € 175 €<br />
gbb Front Marítim 4* 160 € 172 €<br />
Rafael Diagonal Port 4* 157 € 172 €<br />
attica 21 barcelona Mar 4* 157 € 169 €<br />
barceló atenea Mar 4* 115 € 125 €<br />
Holiday Inn barcelona City 4* 104 € 104 €<br />
Hotel del Mar 3* 145 € 175 €<br />
Hotel glories 3* 92 € 129 €<br />
Hotel Ibis barcelona Pza glories 2* 107 € 115 €<br />
Hotel Santa Marta 2* 90 € 105 €<br />
Rates are per room, per night, including taxes and breakfast<br />
Page 30 /// FInal announcement /// eSTRO 31 eSTRO 31 /// FInal announcement /// Page 31
PuRPOSE<br />
MeMbership bership<br />
eSTRO, The european SocieTy for Radiotherapy and<br />
Oncology, was founded in Milan in September 1980.<br />
The purpose of eSTRO is to foster, in all its aspects, radiotherapy<br />
(also known as radiation oncology). To fulfill its<br />
purpose eSTRO will:<br />
a. Develop and promote standards of education in radiotherapy<br />
and clinical oncology,<br />
b. Promote standards of practice in radiotherapy, clinical<br />
oncology and related subjects,<br />
c. Stimulate the exchange of scientific knowledge in all<br />
related fields,<br />
d. Strengthen the clinical speciality of radiotherapy and<br />
clinical oncology in relation to other specialities and<br />
professions involved in cancer management,<br />
e. encourage co-operation with international, regional<br />
and national societies and bodies representing radiotherapy,<br />
clinical oncology and related subjects,<br />
f. Facilitate research and development in radiotherapy,<br />
clinical oncology and related subjects.<br />
package<br />
Society<br />
Dissemination<br />
Professional<br />
Voting right, eligible for councils, committees,<br />
working groups, faculties, etc…<br />
access to green and Red Journal,<br />
reports, webcast library, discount on<br />
eSTRO publications, etc…<br />
Reduced fee for eSTRO <strong>events</strong> and courses,<br />
eligible for grants and awards, etc…<br />
BENEFITS OF ESTRO MEMBERShIP<br />
Improve your proFessIonal development by partIcIpatIng In the<br />
socIety’s ‘InstItutIonal’ actIvItIes<br />
<strong>•</strong> Opportunity to become a member of a Council, Committee<br />
or a Specialist in a Working group,<br />
<strong>•</strong> eligible for grants and awards,<br />
<strong>•</strong> eligible for eSTRO Fellow,<br />
<strong>•</strong> Possibility of networking with other professionals/<br />
experts in your field,<br />
<strong>•</strong> Invitation to contribute to conferences (as a scientific<br />
Committee member or as a speaker).<br />
keep updated WIth ongoIng research<br />
<strong>•</strong> Personal subscription to the green Journal + on line<br />
access,<br />
<strong>•</strong> On line access to the Red Journal,<br />
<strong>•</strong> Regular mailings of eSTRO newsletters and reports.<br />
get dIscounts<br />
<strong>•</strong> Discount on eSTRO Publications,<br />
<strong>•</strong> Discount on conference registration fees,<br />
<strong>•</strong> Discount on eSTRO School programmes,<br />
<strong>•</strong> Reduced subscription to the European Journal of<br />
Cancer.<br />
membershIp type<br />
Full assocIate<br />
Full access no access<br />
Full access Conditional access<br />
Full access Conditional access<br />
FOR FuRThER INFORMATION PLEASE CONTACT:<br />
eSTRO Office <strong>•</strong> av. e. Mounier 83 <strong>•</strong> 1200 brussels <strong>•</strong> belgium<br />
Tel: + 32 2 775 93 40 <strong>•</strong> Fax: + 32 2 779 54 94 <strong>•</strong> email: membership@estro.<strong>org</strong><br />
NOTE: RENEWAL OF ESTRO MEMBERShIP FOR <strong>2012</strong> WILL BE POSSIBLE AS OF OCTOBER, 2011.<br />
ESTRO<br />
31<br />
<strong>2012</strong><br />
Page 32 /// FInal announcement /// eSTRO 31 eSTRO 31 /// FInal announcement /// Page 33